• 1
    Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992–1999. Gynecol Oncol 2005;97:51923.
  • 2
    Thomas GM, Dembo AJ, Hacker NF, DePetrillo AD. Current therapy for dysgerminoma of the ovary. Obstet Gynecol 1987;70:26875.
  • 3
    Williams S, Blessing JA, Liao SY et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol 1994;12:7016.
  • 4
    Segelov E, Campbell J, Ng M et al. Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experience. J Clin Oncol 1994;12:37884.
  • 5
    Gershenson DM. Management of early ovarian cancer: germ cell and sex cord-stromal tumors. Gynecol Oncol 1994;55:S6272.
  • 6
    Dark GG, Bower M, Newlands ES. Surveillance policy for stage I ovarian germ cell tumours. J Clin Oncol 1997;15:6204.
  • 7
    FIGO Cancer Committee. Staging announcement. Gynecol Oncol 1986;25:3835.
  • 8
    Murugaesu N, Schmid P, Dancey G et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol 2006;24:48626.
  • 9
    Bower M, Fife K, Holden L. Chemotherapy for ovarian germ cell tumours. Eur J Cancer 1996;32A:5937.
  • 10
    International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594603.
  • 11
    Zanagnolo V, Sartori E, Galleri G et al. Clinical review of 55 cases of malignant ovarian germ cell tumors. Eur J Gynaecol Oncol 2004;25:31520.
  • 12
    Mayordomo JI, Paz-Ares L, Rivera F et al. Ovarian and extragonadal malignant germ-cell tumors in females: a single-institution experience with 43 patients. Ann Oncol 1994;5:2531.
  • 13
    Zanetta G, Bonazzi C, Cantu M et al. Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001;19:101520.
  • 14
    Marina NM, Cushing B, Giller R et al. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: a Pediatric Oncology Group/Children’s Cancer Group Intergroup Study. J Clin Oncol 1999;17:213743.
  • 15
    Warde P, Specht L, Horwich A et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:444852.
  • 16
    Read G, Stenning SP, Cullen MH et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992;10:17628.
  • 17
    Francis R, Bower M, Brunstrom G et al. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer 2000;36:192532.
  • 18
    Klepp O, Olsson AM, Henrikson H et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group. J Clin Oncol 1990;8:50918.
  • 19
    O’Connor DM, Norris HJ. The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading. Int J Gynecol Pathol 1994;13:2839.
  • 20
    Schwartz PE. Surgery of germ cell tumours of the ovary. Forum (Genova) 2000;10:35565.
  • 21
    Dadmanesh F, Miller DM, Swenerton KD, Clement PB. Gliomatosis peritonei with malignant transformation. Mod Pathol 1997;10:597601.
  • 22
    Norris HJ, Zirkin HJ, Benson WL. Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases. Cancer 1976;37:235972.
  • 23
    Boshoff C, Begent RH, Oliver RT et al. Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol 1995;6:3540.
  • 24
    Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;15:151323.
  • 25
    Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996;14:292332.
  • 26
    Fossa SD. Long-term sequelae after cancer therapy—survivorship after treatment for testicular cancer. Acta Oncol 2004;43:13441.
  • 27
    Oliver RT, Mason MD, Mead GM et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005;366:293300.
  • 28
    Ezzat A, Raja M, Bakri Y. Malignant ovarian germ cell tumours—a survival and prognostic analysis. Acta Oncol 1999;38:45560.
  • 29
    Perrin LC, Low J, Nicklin JL et al. Fertility and ovarian function after conservative surgery for germ cell tumours of the ovary. Aust N Z J Obstet Gynaecol 1999;39:2435.
  • 30
    Gaffan J, Holden L, Newlands ES et al. Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours—a retrospective long-term follow-up study. Br J Cancer 2003;89:184954.
  • 31
    Gershenson DM, Morris M, Cangir A et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 1990;8:71520.
  • 32
    Smales E, Peckham MJ. Chemotherapy of germ-cell ovarian tumours: first-line treatment with etoposide, bleomycin and cisplatin or carboplatin. Eur J Cancer 1987;23:46974.